Regenerative medicine is an interdisciplinary field of research and clinical applications focused on the repair, replacement or regeneration of cells, tissues or organs to restore impaired function resulting from any cause, including congenital defects, disease, trauma and ageing. The main focus of regenerative medicine is the human cells. In order to achieve the purpose of regenerative medicine, several scientists and clinicians have been stimulated to focus on regenerative ideas when dealing with tissue failure due to rapid success seen with early tissue engineering. Recently, financial meltdown has choked biotech by devastating its already floundering inflow of investment funds. However, regenerative medicine is a hope for future medicine as big pharmaceutical corporations have been acquiring some of the most significant biotech, possibly marking a new era where regenerative medicine. This results in making the academic labs of universities and the small boundaries of SMEs opportunity for gainful applications in the marketplace. The quest for regeneration is one of the dreams of mankind, like flying and setting foot on the moon. Stem cells have been becoming the promising way for being induced to differentiate into different purpose cells even some thorny problems are still there. It can be predicted that it is the destiny of mankind to reach for its visions, and therefore regenerative medicine is bound to be the hope for future medicine.
Regenerative Medicine, Engineering, Stem Cell, Organ, Tissue
2. Spadaccio C, Rainer A, Trombetta M, Centola M, Lusini M, Chello M, Covino E, De Marco F, Coccia R, Toyoda Y, Genovese JA. A G-CSF functionalized scaffold for stem cells seeding: a differentiating device for cardiac purposes. J Cell Mol Med. 2011; 15:1096-1108.
3. Gaetani R, Rizzitelli G, Chimenti I, Angelini F, Ionta V, Forte E, Frati G, Schussler O, Barbetta A, Messina E, Dentini M, Giacomello A. Cardiospheres and tissue engineer- ing for myocardial regeneration: po- tential for clinical application. J Cell Mol Med 2011; 32:9271-9281.
4. Choi YS, Dusting GJ, Stubbs S, Arunothayaraj S, Han XL, Collas P, Morrison WA, Dilley RJ. Differentia- tion of human adipose-derived stem cells into beating cardiomyocytes. J Cell Mol Med 2010; 14:878-889.
5. Langer R, Vacanti J. Advances in tissue engineering. J Pediatr Surg 2016; 51:8-12.
6. Buchanan IM, Scott T, Tandle AT, Burgan WE, Burgess TL, Tofilon PJ, Camphausen K. Radiosensitization
of glioma cells by modulation of Met signaling with the hepatocyte growth factor neutralizing antibody, AMG102. J Cell Mol Med 2011; 15:1999-2006.
7. Pneumaticos SG, Triantafyllopoulos GK, Basdra EK, Papavassiliou AG.Segmental bone defects: from cellu- lar and molecular pathways to the development of novel biological treatments. J Cell Mol Med 2010; 14:2561-2569.
8. Matthews LG. Cosmas and Damian - patron saints of medicine and phar- macy their cult in England. Med Hist. 1968; 12:281-288.
9. Damjanov I. Teratocarcinoma: neo- plastic lessons about normal embry- ogenesis. Int J Dev Biol 1993; 37:39- 46.
10. Martin GR. Isolation of a pluripotent cell line from early mouse embryos cultured in medium conditioned by teratocarcinoma stem cells. Proc Natl Acad Sci USA 1981; 78:7634-7638.
11. Evans MJ, Kaufman MH. Establish- ment in culture of pluripotential cells from mouse embryos. Nature 1981; 292:154-156.
12. Thomson JA, Kalishman J, Golos TG, Durning M, Harris CP, Hearn JP. Plu- ripotent cell lines derived from com- mon marmoset (Callithrix jacchus) blastocysts. Biol Reprod 1996; 55:254-259.
13. Beier JP, Klumpp D, Rudisile M, Dersch R, Wendorff JH, Bleiziffer O, Arkudas A, Polykandriotis E, Horch RE, Kneser U. Collagen matrices from sponge to nano: new perspec- tives for tissue engineering of skele- tal muscle. BMC Biotechnol. 2009; 9:34.
14. Polykandriotis E, Euler S, Arkudas A, Pryymachuk G, Beier JP, Greil P, Dragu A, Lametschwandtner A,Kneser U, Horch RE. Regression and persistence: remodelling in a tis- sue engineered axial vascular as- sembly. J Cell Mol Med 2009; 13:4166-4175.
15. Fenn J, Raskino M. Mastering the hype cycle: how to choose the right innovation at the right time. Boston : Mcgraw-Hill Professional; ISBN 978- 1-4221-2110-8. 2008.
16. EurActiv.com PLC. Biotech start-ups turn to US for finance. Last accessed on June 28, 2016. Access at http://www.euractiv.com/en/enterpris e-jobs/biotech-start-ups-turn-to-us- for-finance-news-494455.
17. Brindley D, Davie N. Regenerative medicine through a crisis: social per- ception and the financial reality. Re- juvenation Res 2009;12:455-461.
18. Swetha G, Chandra V, Phadnis S, Bhonde R. Glomerular parietal epi- thelial cells of adult murine kidney undergo EMT to generate cells with traits of renal progenitors. J Cell Mol Med. 2011; 15:396-413.
19. Chen Y, Xiang LX, Shao JZ, Pan RL, Wang YX, Dong XJ, Zhang GR. Re- cruitment of endogenous bone mar- row mesenchymal stem cells towards injured liver. J Cell Mol Med 2010; 14:1494-1508.
20. Cotten M, Fisher K. Autologous cord blood cells for hypoxic ischemic en- cephalopathy study 1. Phase I study of feasibility and safety. North Caroli- na : Duke University; 2008.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.